Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Marker Therapeutics Inc (NASDAQ:MRKR) released preliminary results of the first participant treated with MT-601 in the Phase 1 APOLLO clinical trial. The participant, who had diffuse large B cell lymphoma and had failed four prior lines of therapy, demonstrated a complete metabolic response after treatment with MT-601. The treatment was well tolerated with no reports of higher than Grade 1 treatment-related adverse events. Following the news, MRKR shares are up 11.10% at $6.13.
September 11, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marker Therapeutics' stock is trading higher following the release of promising preliminary results from the Phase 1 APOLLO clinical trial of MT-601. The first participant demonstrated a complete metabolic response, and the treatment was well tolerated.
The positive preliminary results from the Phase 1 APOLLO clinical trial of MT-601 have boosted investor confidence in Marker Therapeutics, leading to an increase in the company's stock price. The fact that the first participant demonstrated a complete metabolic response and the treatment was well tolerated suggests that MT-601 could be a successful treatment option, which would likely lead to increased revenues for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100